Frank Kung net worth and biography

Frank Kung Biography and Net Worth

Director of Amyris
Dr. Frank F. C. Kung Ph.D. serves as Independent Director of the Company. Dr. Kung is a founding member of Vivo Capital LLC (“Vivo”), a healthcare focused investment firm founded in 1996 in Palo Alto, California, whose fund under management is an owner of greater than five percent of the Company’s outstanding common stock. Dr. Kung started his career in the biotechnology industry in 1979 when he joined Cetus Corporation. He later co-founded Cetus Immune Corporation in 1981, which was acquired by its parent company in 1983. In 1983, he co-founded Genelabs Technologies, Inc. where he served as Chairman and CEO until 1995. During his tenure in Genelabs, he brought the company public in 1991, and built it to a 175 employee international biotech company with operations in the United States, Belgium, Singapore, Switzerland and Taiwan. Dr. Kung holds a Bachelor of Science degree in chemistry from the National Tsing Hua University in Taiwan, and a Doctor of Philosophy degree in molecular biology and a Master of Business Administration degree from the University of California, Berkeley.

What is Frank Kung's net worth?

The estimated net worth of Frank Kung is at least $249,600.00 as of September 21st, 2022. Dr. Kung owns 80,000 shares of Amyris stock worth more than $249,600 as of September 28th. This net worth approximation does not reflect any other investments that Dr. Kung may own. Learn More about Frank Kung's net worth.

How do I contact Frank Kung?

The corporate mailing address for Dr. Kung and other Amyris executives is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. Amyris can also be reached via phone at (510) 450-0761 and via email at [email protected] Learn More on Frank Kung's contact information.

Has Frank Kung been buying or selling shares of Amyris?

During the last quarter, Frank Kung has sold $10,623,568.80 of Amyris stock. Most recently, Frank Kung sold 200,000 shares of the business's stock in a transaction on Wednesday, September 21st. The shares were sold at an average price of $3.50, for a transaction totalling $700,000.00. Following the completion of the sale, the director now directly owns 80,000 shares of the company's stock, valued at $280,000. Learn More on Frank Kung's trading history.

Who are Amyris' active insiders?

Amyris' insider roster includes Eduardo Alvarez (COO), Anthony Hughes (CAO), Nicole Kelsey (Insider), Hermanus Kieftenbeld (CFO), Frank Kung (Director), James McCann (Director), and John Melo (CEO). Learn More on Amyris' active insiders.

Are insiders buying or selling shares of Amyris?

During the last year, Amyris insiders bought shares 1 times. They purchased a total of 17,400 shares worth more than $99,354.00. During the last year, insiders at the biotechnology company sold shares 8 times. They sold a total of 2,864,901 shares worth more than $11,026,750.76. The most recent insider tranaction occured on September, 21st when Director Frank Kung sold 200,000 shares worth more than $700,000.00. Insiders at Amyris own 33.8 % of the company. Learn More about insider trades at Amyris.

Information on this page was last updated on 9/21/2022.

Frank Kung Insider Trading History at Amyris

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/21/2022Sell200,000$3.50$700,000.0080,000View SEC Filing Icon  
9/19/2022Sell1,080,676$3.80$4,106,568.80109,460View SEC Filing Icon  
9/15/2022Sell1,385,000$4.20$5,817,000.00458,591View SEC Filing Icon  
4/13/2021Sell4,678,363$14.96$69,988,310.482,266View SEC Filing Icon  
6/5/2020Buy3,689,225$3.00$11,067,675.002,932View SEC Filing Icon  
4/29/2019Buy913,529$4.76$4,348,398.043,599View SEC Filing Icon  
8/20/2018Sell3,924,884$6.22$24,412,778.484,266View SEC Filing Icon  
See Full Table

Frank Kung Buying and Selling Activity at Amyris

This chart shows Frank Kung's buying and selling at Amyris by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amyris Company Overview

Amyris logo
Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.
Read More

Today's Range

Now: $3.17
Low: $2.95
High: $3.20

50 Day Range

MA: $2.88
Low: $1.70
High: $4.05

2 Week Range

Now: $3.17
Low: $1.47
High: $15.12

Volume

136,146 shs

Average Volume

7,360,158 shs

Market Capitalization

$1.03 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.36